Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River Laboratories | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Charles River Laboratories

Discovery and manufacturing services drive growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories

4Q Revenues: $329.5 million (+14%)

4Q Earnings: $27.7 million (+43%)

FY Revenues: $1.3 billion (+11%)

FY Earnings: $128.2 million (+23%)

Comments: Research Models and Services (RMS) revenues were $117.7 million in the quarter, down 4% impacted by exchange rates.  Discovery and Safety Assessment (DSA) was $149.6 million, up 35% driven primarily by the Early Discovery acquisitions, which contributed 24%. Manufacturing revenue was $62.3 million in the quarter, up 11% driven by double-digit growth in the Endotoxin and Microbial Detection business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters